Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
University of Michigan Rogel Cancer Center
Incyte Corporation
Eli Lilly and Company
Peking University
Mayo Clinic
Medical University of South Carolina
University of Alabama at Birmingham
Taiho Oncology, Inc.
QED Therapeutics, a BridgeBio company
Academic and Community Cancer Research United
EpicentRx, Inc.
EMD Serono
University of Texas Southwestern Medical Center
Merck Sharp & Dohme LLC
TerSera Therapeutics LLC
The First Affiliated Hospital with Nanjing Medical University
Boston Scientific Corporation
National Cancer Institute (NCI)
ASLAN Pharmaceuticals
Gilead Sciences
American College of Radiology Imaging Network
Johannes Gutenberg University Mainz
Concordia Laboratories Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Allina Health System
Georgetown University
King Faisal Specialist Hospital & Research Center
Centre Hospitalier Universitaire de Besancon
New Mexico Cancer Research Alliance
AIO-Studien-gGmbH
NYU Langone Health
Masonic Cancer Center, University of Minnesota
Chinese University of Hong Kong
Peking University
European Organisation for Research and Treatment of Cancer - EORTC
Emory University
Japan Clinical Oncology Group
Stanford University
AstraZeneca
Amgen
University Hospital, Gasthuisberg
SWOG Cancer Research Network
IRCCS San Raffaele
Arbeitsgemeinschaft medikamentoese Tumortherapie
University of Southern California
Amgen
National Cancer Institute (NCI)
Centre Hospitalier Universitaire Vaudois
European Organisation for Research and Treatment of Cancer - EORTC